Print View Attached Docs:
42900:CANCER ANTIGEN 19-9 (CA 19-9)
Alias Names:CA19-9 / CA 19.9 / CA 19 9
Methodology:Chemiluminescence (CL)
Edit Date:4/25/2008
Performed:Daily
Released:Same day as tested
CPT Code:86301
Specimen Collection Details
Collection:One 7.5 mL serum separator tube (SST). Also acceptable: One 5 mL gold serum separator top tube (SST), one 4 mL green top tube (heparin), or one 4.5 mL light green top plasma separator tube (PST).
Handling:Allow to clot, centrifuge and separate serum or plasma from cells within 2 hours of collection. Refrigerate. Freeze at -20° C or colder if specimen cannot be assayed wtihin 48 hours. Allow no more than one freeze/thaw cycle. If multiple tests are ordered, send separate specimen for this test.
Stability:48 hours refrigerated or 3 months frozen. Unstable ambient.
Standard Volume:1.0 mL serum or plasma.
Minimum Volume:0.4 mL serum or plasma.
Transport:Refrigerated, or frozen on dry ice.
Comments:The Beckman DXI CA 19-9 method is used. Results obtained with different assay methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. The CA 19-9 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Rejection Criteria:Gross lipemia or hemolysis; specimen frozen and thawed more than once.

MEDICARE MAY REQUIRE A SIGNED ADVANCE BENEFICIARY NOTICE (ABN) FOR THIS TEST
Reference Range:
0-35 U/mL